Chondroid syringoma is a cutaneous adnexal tumor originating from sweat glands origin. It is rare in occurrence and usually benign, having an incidence of 0.01 to 0.098%. As these tumors are uncommon, their diagnosis is missed many times and are misdiagnosed. Hence in any case of facial skin swelling increasing slowly in size, this entity should be kept in mind as one of the possibilities and differential diagnosis. Histopathological examination of the excision biopsy gives the definitive confirmatory diagnosis. Surgically excising the swelling locally along with a surrounding normal tissue cuff is the standard treatment given which prevents recurrence. Hereby we present a 35-year-old case of facial chondroid syringoma having a focal component of eccrine hidrocystoma, keratinous cyst as well as syringocystadenoma papilliferum on the chin that was clinically suspected to be an epidermoid cyst or mucocele.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985670 | PMC |
http://dx.doi.org/10.7759/cureus.34571 | DOI Listing |
Am J Otolaryngol
December 2024
Department of Otolaryngology - Head & Neck Surgery, University of Michigan, Ann Arbor, MI, USA. Electronic address:
Purpose: We examined operative efficiency, rate of facial nerve paresis, and post-operative outcomes in patients undergoing retrograde (RGD) vs anterograde dissection (AGD) of the facial nerve controlling for tumor location.
Methods: Single-institution, retrospective analysis of patients with benign parotid tumors undergoing superficial parotidectomy with facial nerve dissection over a six-year period. Operative and pathology reports were reviewed to classify tumor size, location in relation to facial nerve branches, and technique for facial nerve dissection.
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. We reviewed our experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland.
View Article and Find Full Text PDFRadiol Case Rep
February 2025
Department of Radiology, National Institute of Oncology, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Rabat, Morocco.
Pleomorphic adenoma (PA) is the most common benign histological form of salivary gland tumors, particularly in the parotid gland, primarily affecting women between the ages of 40 and 60. However, its occurrence in the trachea is very rare. This article reports the case of a 48-year-old woman presenting with progressive dyspnea and weight loss, initially suspected of having a pulmonary embolism.
View Article and Find Full Text PDFBMC Oral Health
December 2024
Department of Oral and Maxillofacial Surgery, Xuchang Central Hospital, Henan, China.
Objectives: This study explored the suitability of local anaesthesia with conscious sedation for parotid gland tumour surgery.
Methods: Three hundred sixty-four medical records were reviewed to gather data on several key aspects for retrospective analysis. These included age, incision length, operation time, tumour size, NNIS score, ASA score, and pathology.
Int J Mol Sci
November 2024
Department of Otolaryngology, Academy of Applied Medical and Social Sciences, 82-300 Elblag, Poland.
Salivary gland tumors are rare head and neck tumors constituting up to 6% of all head and neck neoplasms; despite being mostly benign, these tumors present in diverse histological subtypes, making them challenging to diagnose and treat. Our research aims to investigate the link between inflammation and tumorigenesis within the salivary glands based on the literature regarding the etiopathogenesis of benign salivary gland tumors. This scoping review was conducted following the PRISMA extension for scoping reviews and reporting guidelines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!